Business
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
KZR-616 MISSION Phase 1b study results support continued development for multiple immune mediated diseases Investigational new drug (IND) application filed
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nKZR-616 MISSION Phase 1b study results support continued development for multiple immune mediated diseases\n\n\nInvestigational new drug (IND) application filed for first-in-class protein secretion inhibitor, KZR-261\n\n\nExpertise in autoimmune drug development added with appointment of Micki Klearman, MD, to Board of Directors and creation of Clinical Advisory Committee\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2021 financial results and corporate highlights.\n\n“We were pleased this quarter to share the final data update from our completed Phase 1b portion of the MISSION study, building on the positive safety, tolerability and early efficacy profile of KZR-616. I commend the entire team at Kezar on another quarter of outstanding execution across both of our programs and look forward to providing meaningful updates from both before the end of the year,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer. “We are also pleased to announce that Kezar recently submitted an IND application to the FDA for KZR-261, our first-in-class protein secretion inhibitor. Like the platform potential we see for KZR-616 in autoimmunity, we believe KZR-261 could have broad potential across the oncology landscape. We look forward to sharing more about our planned Phase 1 trial design and the potential of our protein secretion drug discovery platform in the coming months.”\n\nClinical Highlights & Updates\n\nKZR-616: Selective Immunoproteasome Inhibitor\n\nMISSION – Phase 2 clinical trial in patients with lupus nephritis (LN) (NCT03393013)\n\nAt the European Congress of Rheumatology (EULAR 2021) in June, Kezar presented final clinical data from the completed Phase 1b dose escalation portion of the MISSION study in 47 patients with systemic lupus erythematous, including two patients with active proliferative LN. KZR-616 demonstrated improvement across all exploratory efficacy measures and was well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks. In the two patients with LN, improvements in renal function correlated with reductions in a key biomarker of kidney inflammation, uCD163.\n\n\nThe safety a...